A gene signature of loss of oestrogen receptor (ER) function and oxidative stress links ER-positive breast tumours with an absent progesterone receptor and a poor prognosis

Breast Cancer Research

Volumn 10, Issue 5, 2008, Pages

  Neven, Patrick ^a   Van Gorp, Toon ^a   Deraedt, Karen ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR PROTEIN;

ADENOCARCINOMA; BREAST TUMOR; CELL DIVISION; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; METABOLISM; MORTALITY; NEOPLASM; NOTE; OXIDATIVE STRESS; PHENOTYPE; PROGNOSIS;

ADENOCARCINOMA; BREAST NEOPLASMS; CELL DIVISION; ESTROGENS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; OXIDATIVE STRESS; PHENOTYPE; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 59449084470     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2135     Document Type: Editorial

References (17)

1. Yau C, Benz CC. Genes responsive to both oxidant stress and loss of estrogen receptor function identify a poor prognosis group of ER-positive primary breast cancers. Breast Cancer Res 2008, 10:R61. 10.1186/bcr2120, 18631401.
2. Oh DS, Troester MA, Usary J, Hu Z, He X, Fan C, Wu J, Carey LA, Perou CM. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 2006, 24:1656-1664. 10.1200/JCO.2005.03.2755, 16505416.
3. Liang X, Lu B, Scott GK, Chang CH, Baldwin MA, Benz CC. Oxidant stress impaired DNA-binding of estrogen receptor from human breast cancer. Mol Cell Endocrinol 1998, 146:151-161. 10.1016/S0303-7207(98)00161-0, 10022773.
4. Perou CM, Sørlie T, Eisen MB, Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
5. Creighton CJ, Kent Osborne C, Vijver MJ, Foekens JA, Klijn JG, Horlings HM, Nuyten D, Wang Y, Zhang Y, Chamness GC, Hilsenbeck SG, Lee AV, Schiff R. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat 2008 Apr 19.
6. Dairkee SH, Nicolau M, Sayeed A, Champion S, Ji Y, Moore DH, Yong B, Meng Z, Jeffrey SS. Oxidative stress pathways highlighted in tumor cell immortalization: association with breast cancer outcome. Oncogene 2007, 26:6269-6279. 10.1038/sj.onc.1210452, 17471242.
7. Scott GK, Kushner P, Vigne JL, Benz CC. Truncated forms of DNA-binding estrogen receptors in human breast cancer. J Clin Invest 1991, 88:700-706. 295419, 1864980, 10.1172/JCI115356.
8. Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, Lawrence R, Deneke S, Herrera R, Chamness GC, Fuqua SA, Brown PH, Osborne CK. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumours in vivo. J Natl Cancer Inst 2000, 92:1926-1934. 10.1093/jnci/92.23.1926, 11106684.
9. Quong J, Eppenberger-Castori S, Moore D, Scott GK, Birrer MJ, Kueng W, Eppenberger U, Benz CC. Age-dependent changes in breast cancer hormone receptors and oxidant stress markers. Breast Cancer Res Treat 2002, 76:221-236. 10.1023/A:1020886801674, 12462383.
10. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 2005, 23:7721-7735. 10.1200/JCO.2005.09.004, 16234531.
11. Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, Berteloot P, Amant F, Vergote I, Christiaens MR. Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol 2005, 58:611-616. 1770673, 15917412, 10.1136/jcp.2004.022772.
12. Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, Syrjäkoski K, Kallioniemi A, Kilpivaara O, Mannermaa A, Kosma VM, Uusitupa M, Eskelinen M, Kataja V, Aittomäki K, von Smitten K, Heikkilä P, Lukas J, Holli K, Bartkova J, Blomqvist C, Bartek J, Nevanlinna H. NAD(P)H:quinone oxidoreductase 1 NQ,2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 2008, 40:844-853. 10.1038/ng.155, 18511948.
13. Banerjee M, George J, Song EY, Roy A, Hryniuk W. Tree-based model for breast cancer prognostication. J Clin Oncol 2004, 22:2567-2575. 10.1200/JCO.2004.11.141, 15226324.
14. Brouckaert O, Pintens S, Van Belle V, Van Huffel S, Camerlynck E, Amant F, Leunen K, Smeets A, Berteloot P, Van Limbergen E, Decock J, Hendrickx W, Weltens C, Bogaert W, Bempt I, Drijkoningen M, Paridaens R, Wildiers H, Vergote I, Christiaens MR, Neven P. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors. Breast Cancer Res Treat 2008 Jul 16.
15. Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, Berteloot P, Amant F, Christiaens MR, Vergote I. Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related. Breast Cancer Res Treat 2005, 91:81-87. 10.1007/s10549-004-8235-8, 15868434.
16. Gaudet MM, Britton JA, Kabat GC, Steck-Scott S, Eng SM, Teitelbaum SL, Terry MB, Neugut AI, Gammon MD. Fruits, vegetables, and micronutrients in relation to breast cancer modified by menopause and hormone receptor status. Cancer Epidemiol Biomarkers Prev 2004, 13:1485-1494.
17. Cui Y, Shikany JM, Liu S, Shagufta Y, Rohan TE. Selected antioxidants and risk of hormone receptor-defined invasive breast cancers among postmenopausal women in the Women's Health Initiative Observational Study. Am J Clin Nutr 2008, 87:1009-1018.